KOSDAQRetail & Consumer031860

DHX Company

₩6,930 0.00%2026-11-18 close
Market Cap
₩18.7B
Turnover
₩0
Volume
0 shares
Shares out.
2.7M
PER
—
PBR
0.8×
EPS
-₩9,329
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses, a trading halt and a reshaped board at DHX Company

Third-quarter 2026 revenue fell to KRW 603 million and attributable net income swung to a KRW 911 million profit, but the company posted operating losses in each year from 2022 to 2025 and trading in its shares has been suspended since April 3, 2026.

  1. 1

    Operating losses were KRW 6.47 billion, KRW 13.1 billion, KRW 6.12 billion and KRW 7.83 billion for 2022 to 2025, a loss in each of the four years, while 2025 revenue of KRW 14.5 billion was the largest of the period.

  2. 2

    A disclaimer of opinion on the 2025 audit led to a trading suspension from April 3, 2026, and a remediation period was granted in a disclosure dated April 20, 2026.

  3. 3

    Third-quarter 2026 revenue was KRW 603 million, down 85.0% year on year, with an operating loss of KRW 1.46 billion, while attributable net income turned to a KRW 911 million profit.

  4. 4

    The chief executive changed several times in 2026, the extraordinary shareholders' meeting on November 4, 2026 rejected the independent director nominations, and an embezzlement and breach-of-trust matter was disclosed on October 13, 2026.

  5. 5

    The debt-to-equity ratio rose to 101.0% at the end of 2025 from 18.9% in 2024, and a KRW 15.0 billion convertible bond issue was decided in March 2026.

02

Business structure

DHX Company was founded in 1979 and listed on KOSDAQ in 1997. Its core business is ICT device distribution; after ending its computer and peripheral distribution business, it expanded into distributing e-cigarettes, cosmetics, agricultural products and F&B.

The bio segment covers R&D and manufacturing of the medical devices Hemapure and NeuroHarmony, the pharmaceutical Apitoxin, and bio-cosmetics.

This structure is based on a company profile dated September 2025, while a May 2026 report on the first-quarter filing described the business as ICT distribution, bicycle manufacturing and bio operations. As of March 31, 2026, the company had five unlisted consolidated subsidiaries.

Its largest shareholder changed to Prime Core, which holds a 29.7% stake, after a third-party rights offering was paid in on April 7, 2026, and Prime Core's main business is listed as wholesale and retail.

Press reports said the company obtained a 20.68% stake in a Nasdaq-listed company, but the carrying value and accounting treatment should be confirmed in the periodic report.

ICT device distribution economics depend on supply pricing and securing customers, and the move into consumer products is read as an effort to diversify the customer base.

Because the bio portfolio spans medical devices, pharmaceuticals and cosmetics R&D, each unit's size and profit contribution should be confirmed from segment information in the next periodic report.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4B-₩1.5B−37.3%
2025Q4₩3B-₩2.5B−81.1%
2026Q1₩3.2B-₩1.9B−60.8%
2026Q2₩3.4B-₩1.1B−33.4%
2026Q3₩600M-₩1.5B−242.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩8.3B-₩6.5B-₩14.5B−77.6%−24.3%38.5%
2023₩11.3B-₩13.1B-₩31.7B−115.6%−52.7%10.6%
2024₩9.5B-₩6.1B-₩17.6B−64.1%−36.5%18.9%
2025₩14.5B-₩7.8B-₩33.2B−54.0%−148.7%101.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

In the annual figures from the periodic reports, revenue was KRW 8.35 billion in 2022, KRW 11.3 billion in 2023 (up 35.5% year on year), KRW 9.54 billion in 2024 (down 15.6%) and KRW 14.5 billion in 2025 (up 52.0%), making 2025 the largest year of 2022 to 2025 and 2022 the smallest.

Operating losses were KRW 6.47 billion, KRW 13.1 billion, KRW 6.12 billion and KRW 7.83 billion for 2022 to 2025, a loss in each of those four years. Operating margins were -77.6%, -115.6%, -64.1% and -54.0%, so in 2025 the ratio improved even though the operating loss grew, because revenue rose 52.0%.

Attributable net losses were KRW 14.5 billion, KRW 31.7 billion, KRW 17.6 billion and KRW 33.2 billion for 2022 to 2025. The net loss including non-controlling interests was KRW 34.4 billion in 2025, well above the operating loss, which points to a heavy non-operating burden.

In a provisional result disclosed on March 14, 2025 for fiscal 2024, the company attributed the revenue decline to changes from new customers and a higher cost ratio, and the smaller operating loss to lower bad-debt charges on receivables that reduced selling and administrative expenses.

The debt-to-equity ratio rose from 18.9% in 2024 to 101.0% in 2025, and total equity at the end of 2025 of KRW 20.3 billion was smaller than the equity attributable to controlling shareholders of KRW 22.3 billion.

Operating cash outflows were KRW 11.3 billion, KRW 7.49 billion, KRW 5.68 billion and KRW 8.86 billion in 2022 to 2025.

Quarterly revenue ran KRW 4.01 billion in 3Q 2025, KRW 3.04 billion in 4Q 2025 (down 24.2% quarter on quarter), KRW 3.19 billion in 1Q 2026 and KRW 3.42 billion in 2Q 2026 (up 7.0%), then fell to KRW 603 million in 3Q 2026 (down 82.4% quarter on quarter and 85.0% year on year).

Quarterly operating losses widened from KRW 1.5 billion in 3Q 2025 to KRW 2.46 billion in 4Q 2025, narrowed to KRW 1.94 billion in 1Q 2026 and KRW 1.14 billion in 2Q 2026, and stood at KRW 1.46 billion in 3Q 2026.

Attributable net loss was KRW 22.5 billion in 4Q 2025, and attributable net income of KRW 911 million in 3Q 2026 marked a swing to profit. The attributable net losses for the last four quarters, from 4Q 2025 to 3Q 2026, totaled KRW 25.2 billion.

The swing to profit came while operating losses continued, so whether non-operating or one-off items drove it should be checked against the income detail in the next periodic report.

05

Industry analysis

The outlook for ICT device distribution rests on a September 2025 company profile analysis that cited rising ICT demand from AI servers and data center investment. Whether that demand reached the company's revenue has to be tested against the third-quarter 2026 figure of KRW 603 million.

Quarterly revenue moved sharply, from KRW 4.01 billion in 3Q 2025 to KRW 603 million in 3Q 2026, which points to unstable customer and volume coverage. Broadening into e-cigarettes, cosmetics, agricultural products and F&B reduces dependence on a single ICT category.

Consumer distribution is a competitive field with large retail operators, and the company's revenue scale is far smaller than that of large listed peers in the same consumer distribution group, including POSCO International, Coway, BGF retail, GS Retail and E-Mart.

A gap in scale of this kind tends to translate into weaker bargaining power with suppliers and customers. The bio segment includes medical devices and pharmaceuticals, where approval requirements and sales channels act as barriers to entry.

Industry judgment therefore depends on whether ICT demand shows up in company revenue and on how much the consumer and bio lines actually contribute.

06

Outlook

The next periodic report is the 2026 annual report, which will show full-year 2026 revenue, operating loss and the audit opinion. Quarterly results for 1Q to 3Q 2026 are already on file, so the full-year total will be read on top of that trend.

Whether the disclaimer of opinion on the 2025 audit is resolved in the audit of the 2026 annual report is the key variable for continued listing.

The KRW 15.0 billion convertible bond decided on March 10, 2026 can be converted from March 10, 2027, and at a conversion price of KRW 500 it corresponds to 30 million common shares.

The 8.02 million new shares issued in the April 7, 2026 third-party rights offering are subject to a one-year lock-up from the date of share delivery, and the subscription amount was KRW 4.01 billion at KRW 500 per share.

On governance, Lee Byung-joon was appointed chief executive by the board on November 4, 2026, and at the same day's extraordinary shareholders' meeting the nominations of Lee Byung-joon and Im Tak-gi as inside directors passed.

The nominations of two independent directors and the auditor appointment and removal items were rejected, so board composition may change at a later shareholders' meeting.

A complainant filed a withdrawal of the embezzlement and breach-of-trust complaint on November 17, 2026, but the company stated that the withdrawal does not mean a finding on guilt or final closure of the criminal case.

The value and accounting treatment of the Nasdaq-listed stake, and the profit contribution of the bicycle and bio businesses, should be checked in the annual report notes and segment information.

07

Valuation

PER
—
PBR
0.8×
ROE
-75.8%
EPS
-₩9,329
BPS
₩8,644
Dividend per share
₩0

Because the attributable net losses for the last four quarters, from 4Q 2025 to 3Q 2026, total KRW 25.2 billion, the price-to-earnings ratio cannot be calculated. With no earnings-based multiple available, the share price is more closely tied to net asset value and expectations for business recovery.

The price-to-book ratio sits in a range below book value per share, which means the stock trades at a discount to net assets.

However, total equity at the end of 2025 of KRW 20.3 billion was smaller than the equity attributable to controlling shareholders of KRW 22.3 billion, so book net assets cannot be carried straight over as value. The dividend yield is effectively zero, so no shareholder return through dividends has appeared.

The stock was subject to a trading suspension from April 3, 2026, so its price formation has run differently from that of a typical listed stock.

Press coverage of the Nasdaq-listed stake can be read as a change on the asset side, but how that stake is carried on the books determines how net assets should be interpreted. When comparing valuation, the operating loss scale and capital structure changes in the 2026 annual report should be checked together.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Narrowing quarterly losses and a profit swing

Operating losses narrowed from KRW 2.46 billion in 4Q 2025 to KRW 1.14 billion in 2Q 2026, and attributable net income turned to a KRW 911 million profit in 3Q 2026. Attributable net losses also shrank to KRW 1.92 billion in 1Q 2026 and KRW 1.71 billion in 2Q 2026.

Whether the 3Q 2026 profit is one-off or sustainable still needs to be confirmed in the periodic report, but the direction of quarterly results is a disclosed fact.

Capital support and a reported overseas stake

The third-party rights offering paid in on April 7, 2026 brought in KRW 4.01 billion and reinforced capital. On the same day the largest shareholder changed to Prime Core, and the new shares are subject to a one-year lock-up.

Press reports of a 20.68% stake in a Nasdaq-listed company could change the asset base if that stake is carried at value on the books.

ICT demand recovery and broader product lines

An analysis dated September 2025 pointed to a recovery in ICT demand driven by AI server and data center investment. The company has broadened its lines into e-cigarettes, cosmetics, agricultural products and F&B, and its bio business includes medical devices and pharmaceuticals.

Whether this diversification reduces revenue volatility should be checked against segment revenue in the 2026 annual report.

09

Bear factors

Revenue collapse and continued operating losses

Third-quarter 2026 revenue of KRW 603 million fell 82.4% from the prior quarter and 85.0% year on year. The operating loss of KRW 1.46 billion in the same quarter extends a run of losses across the last five quarters.

Given attributable net losses of KRW 25.2 billion over the last four quarters, the single-quarter profit is small relative to the accumulated deficit.

Disclaimer of opinion and listing requirements

A disclaimer of opinion on the 2025 audit led to a suspension of trading from April 3, 2026. The delisting ground was cited as the disclaimer caused by a limitation on audit scope, and a remediation period was granted in the April 20, 2026 disclosure. If the audit opinion is not resolved within that period, a decision on whether to delist would follow.

Governance and legal disputes

The board removed co-CEO Cho Young-jung on September 1, 2026, and a court rejected his injunction against the removal on October 27, 2026. A disclosure dated October 13, 2026 reported an embezzlement and breach-of-trust matter involving KRW 4.05 billion, equal to 8.24% of equity.

At the November 4, 2026 extraordinary shareholders' meeting, the independent director nominations were rejected, and on the same day Chung Young-jin resigned and Lee Byung-joon was appointed chief executive.

10

Risk factors

Listing status and trading suspension

The disclaimer of opinion on the 2025 audit was cited as a delisting ground. Trading has been suspended since April 3, 2026, and a remediation period is in place. If the 2026 annual report due at the end of March 2027 does not resolve the audit opinion, a delisting decision would follow. This risk determines listing status separately from business performance.

Governance and internal controls

The chief executive changed several times in 2026, and two independent director nominations and the auditor appointment and removal items were rejected. The embezzlement and breach-of-trust matter disclosed on October 13, 2026 involved KRW 4.05 billion.

The complainant withdrew the complaint on November 17, 2026, but the company stated that the withdrawal does not mean a finding on guilt or final closure of the criminal case.

Financial burden and share dilution

The debt-to-equity ratio rose to 101.0% at the end of 2025 from 18.9% in 2024. The KRW 15.0 billion convertible bond decided on March 10, 2026 can be converted from March 10, 2027, and at a KRW 500 conversion price it could result in 30 million new common shares. The 8.02 million shares issued in the April 2026 rights offering are also under a one-year lock-up.

11

What to watch next

  1. March 10, 2027

    The conversion request period for the 34th convertible bond begins. The 30 million common shares at a KRW 500 conversion price mark the point at which the scale of share dilution can be gauged.

  2. End of March 2027

    This is the statutory filing deadline for the 2026 annual report. Full-year 2026 revenue, operating loss and the audit opinion will be disclosed together, and this is the first point at which the 2025 disclaimer of opinion can be judged as resolved or not.

  3. Early April 2027

    This is the end of the remediation period, roughly ten days after the day following the statutory filing deadline, after which a decision on delisting follows. It is the point at which resumption of trading and continued listing can be confirmed.

12

Overall view

DHX Company's disclosed results show operating losses in each year from 2022 to 2025. Revenue peaked at KRW 14.5 billion in 2025, but that year still carried an operating loss of KRW 7.83 billion and an attributable net loss of KRW 33.2 billion.

Quarterly operating losses narrowed from KRW 1.94 billion in 1Q 2026 to KRW 1.14 billion in 2Q 2026 before widening to KRW 1.46 billion in 3Q 2026, and revenue fell to KRW 603 million in 3Q 2026.

The swing to an attributable net income of KRW 911 million in the same quarter reads as a change in direction, but it came while operating losses continued, so its cause should be confirmed in the periodic report.

On the bull side are the improvement in quarterly results, capital strengthened by a KRW 4.01 billion rights offering, and press reports of an overseas stake.

On the bear side are the trading suspension and delisting ground tied to the disclaimer of opinion, the chief executive changes and rejected independent director nominations, the embezzlement and breach-of-trust disclosure, and a debt-to-equity ratio of 101.0% together with possible convertible bond dilution.

The key checkpoints are the audit opinion and operating loss in the 2026 annual report due by the end of March 2027, and the conversion window opening on March 10, 2027. Listing requirements and earnings recovery are being judged at the same time, so both need to be followed together.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.wisereport.co.kr
  2. kr.investing.com
  3. hongcenter.com
  4. kpinfo.kr
  5. news.nate.com
  6. sentv.co.kr
  7. topstarnews.net
  8. digitaltoday.co.kr
  9. datatooza.com
  10. m.news.nate.com
  11. digitaltoday.co.kr
  12. digitaltoday.co.kr
  13. specialtimes.co.kr
  14. news.nate.com
  15. m.news.nate.com
  16. topstarnews.net

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis